Press Releases

Aug 11, 2026

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Jul 20, 2026

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

Jul 17, 2026

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Jul 06, 2026

Kalaris Appoints Laurie Keating to Board of Directors

Jun 23, 2026

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Jun 12, 2026

Kalaris to Present at Clinical Trials at the Summit 2026

May 12, 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Mar 17, 2026

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Jan 28, 2026

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting